Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results (n=23) comparing transcriptome and kinome profiles before and after treatment with FDA-approved anti-HER2 drugs and combinations, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.